Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
09 mai 2023 02h00 HE
|
Verona Pharma plc
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support...
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
02 mai 2023 02h00 HE
|
Verona Pharma plc
12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
25 avr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
10 avr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
07 mars 2023 02h00 HE
|
Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...
Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
21 févr. 2023 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
20 déc. 2022 02h00 HE
|
Verona Pharma plc
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
19 déc. 2022 16h01 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 02h00 HE
|
Verona Pharma plc
Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m....
Verona Pharma Announces November 2022 Investor Conference Participation
02 nov. 2022 03h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following...